SynthesisPloS one2013
Candidate microRNA biomarkers in human gastric cancer: a systematic review and validation study.
Synthesis in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- Computational identification and validation of non-coding rna biomarkers in gastrointestinal cancer.Functional & integrative genomics · 2025Review
- Hsa_circ_0008344 Promotes Glioma Tumor Progression and Angiogenesis Presumably by Regulating miR-638/SZRD1 Pathway.Neurotoxicity research · 2022Article
- Article
- Diagnostic and therapeutic potencies of miR-18a-5p in mixed-type gastric adenocarcinoma.Journal of cellular biochemistry · 2021Article
- RNF11 at the Crossroads of Protein Ubiquitination.Biomolecules · 2020Review
- MicroRNA and liver cancer.Cancer drug resistance (Alhambra, Calif.) · 2020Review
- A mathematical model as a tool to identify microRNAs with highest impact on transcriptome changes.BMC genomics · 2019Article
- Mechanistic Computational Models of MicroRNA-Mediated Signaling Networks in Human Diseases.International journal of molecular sciences · 2019Review
- Novel role of microRNA-126 in digestive system cancers: From bench to bedside.Oncology letters · 2019Review
- SOX2 interferes with the function of CDX2 in bile acid-induced gastric intestinal metaplasia.Cancer cell international · 2019Article
- Expression of miR-520c in intestinal type gastric adenocarcinoma.Journal of gastrointestinal oncology · 2018Article
- MicroRNA-17 as a promising diagnostic biomarker of gastric cancer: An investigation combining TCGA, GEO, meta-analysis, and bioinformatics.FEBS open bio · 2018Article
- miR-613 inhibits gastric cancer progression through repressing brain derived neurotrophic factor.Experimental and therapeutic medicine · 2018Article
- MiR-638 acts as a tumor suppressor gene in gastric cancer.Oncotarget · 2017Article
- Subconjunctival injection of antagomir-21 alleviates corneal neovascularization in a mouse model of alkali-burned cornea.Oncotarget · 2017Article
- Identification and functional characterization of microRNAs reveal a potential role in gastric cancer progression.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017Article
- Network analysis based on TCGA reveals hub genes in colon cancer.Contemporary oncology (Poznan, Poland) · 2017Article
- Evaluation of Plasma MicroRNAs as Diagnostic and Prognostic Biomarkers in Pancreatic Adenocarcinoma: miR-196a and miR-210 Could Be Negative and Positive Prognostic Markers, Respectively.BioMed research international · 2017Article
- MicroRNA-320 inhibits invasion and induces apoptosis by targeting CRKL and inhibiting ERK and AKT signaling in gastric cancer cells.OncoTargets and therapy · 2017Article
- miR-638 Inhibits immature Sertoli cell growth by indirectly inactivating PI3K/AKT pathway via SPAG1 gene.Cell cycle (Georgetown, Tex.) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) remains a major cause of morbidity and mortality worldwide and there is therefore a clear need to search for more sensitive early diagnostic biomarkers. We performed a systematic review of eight published miRNA profiling studies that compared GC tissues with adjacent noncancerous tissues. A miRNA ranking system was used that took the frequency of comparisons, direction of differential expression and total sample size into consideration. We identified five miRNAs that were most consistently reported to be upregulated (miR-21, miR-106b, miR-17, miR-18a and miR-20a) and two miRNAs that were downregulated (miR-378 and miR-638). Six of these were further validated in 32 paired sets of GC and adjacent noncancerous tissue samples using real-time PCR. MiR-21, miR-106b, miR-17, miR-18a and miR-20a were confirmed to be upregulatedin GC tissues, while the expression of miR-378 was decreased. Moreover, we found a significant association between expression levels of miR-21, miR-106b, miR-17, miR-18a and miR-20a and clinicopathological features of GC. These miRNAs may be used for diagnostic and/or prognostic biomarkers for GC and therefore warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.